These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 16970918)
21. A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/TRAIL-induced apoptosis. Weinmann L; Wischhusen J; Demma MJ; Naumann U; Roth P; Dasmahapatra B; Weller M Cell Death Differ; 2008 Apr; 15(4):718-29. PubMed ID: 18202704 [TBL] [Abstract][Full Text] [Related]
22. The p53 tumor suppressor: a master regulator of diverse cellular processes and therapeutic target in cancer. Farnebo M; Bykov VJ; Wiman KG Biochem Biophys Res Commun; 2010 May; 396(1):85-9. PubMed ID: 20494116 [TBL] [Abstract][Full Text] [Related]
23. p53 reactivation with induction of massive apoptosis-1 (PRIMA-1) inhibits amyloid aggregation of mutant p53 in cancer cells. Rangel LP; Ferretti GDS; Costa CL; Andrade SMMV; Carvalho RS; Costa DCF; Silva JL J Biol Chem; 2019 Mar; 294(10):3670-3682. PubMed ID: 30602570 [TBL] [Abstract][Full Text] [Related]
24. PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. Lambert JM; Gorzov P; Veprintsev DB; Söderqvist M; Segerbäck D; Bergman J; Fersht AR; Hainaut P; Wiman KG; Bykov VJ Cancer Cell; 2009 May; 15(5):376-88. PubMed ID: 19411067 [TBL] [Abstract][Full Text] [Related]
25. PRIMA-1MET induces mitochondrial apoptosis through activation of caspase-2. Shen J; Vakifahmetoglu H; Stridh H; Zhivotovsky B; Wiman KG Oncogene; 2008 Nov; 27(51):6571-80. PubMed ID: 18663359 [TBL] [Abstract][Full Text] [Related]
26. PRIMA-1 induces apoptosis in acute myeloid leukaemia cells with p53 gene deletion. Nahi H; Merup M; Lehmann S; Bengtzen S; Möllgård L; Selivanova G; Wiman KG; Paul C Br J Haematol; 2006 Jan; 132(2):230-6. PubMed ID: 16398657 [TBL] [Abstract][Full Text] [Related]
28. Characterizing the sphingomyelinase pathway triggered by PRIMA-1 derivatives in lung cancer cells with differing p53 status. Soans E; Evans SC; Cipolla C; Fernandes E Anticancer Res; 2014 Jul; 34(7):3271-83. PubMed ID: 24982331 [TBL] [Abstract][Full Text] [Related]
29. Pharmacological reactivation of mutant p53: from protein structure to the cancer patient. Wiman KG Oncogene; 2010 Jul; 29(30):4245-52. PubMed ID: 20498645 [TBL] [Abstract][Full Text] [Related]
30. Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database. Bykov VJ; Issaeva N; Selivanova G; Wiman KG Carcinogenesis; 2002 Dec; 23(12):2011-8. PubMed ID: 12507923 [TBL] [Abstract][Full Text] [Related]
31. Spatiotemporal activation of caspase-dependent and -independent pathways in staurosporine-induced apoptosis of p53wt and p53mt human cervical carcinoma cells. Nicolier M; Decrion-Barthod AZ; Launay S; Prétet JL; Mougin C Biol Cell; 2009 Jun; 101(8):455-67. PubMed ID: 19216720 [TBL] [Abstract][Full Text] [Related]
32. PRIMA-1 synergizes with adriamycin to induce cell death in non-small cell lung cancer cells. Magrini R; Russo D; Ottaggio L; Fronza G; Inga A; Menichini P J Cell Biochem; 2008 Aug; 104(6):2363-73. PubMed ID: 18442053 [TBL] [Abstract][Full Text] [Related]
33. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Bykov VJ; Issaeva N; Shilov A; Hultcrantz M; Pugacheva E; Chumakov P; Bergman J; Wiman KG; Selivanova G Nat Med; 2002 Mar; 8(3):282-8. PubMed ID: 11875500 [TBL] [Abstract][Full Text] [Related]
34. Targeting mutant p53 protein and the tumor vasculature: an effective combination therapy for advanced breast tumors. Liang Y; Besch-Williford C; Benakanakere I; Thorpe PE; Hyder SM Breast Cancer Res Treat; 2011 Jan; 125(2):407-20. PubMed ID: 20349129 [TBL] [Abstract][Full Text] [Related]
35. PRIMA-1(met) radiosensitizes prostate cancer cells independent of their MTp53-status. Supiot S; Zhao H; Wiman K; Hill RP; Bristow RG Radiother Oncol; 2008 Mar; 86(3):407-11. PubMed ID: 18237796 [TBL] [Abstract][Full Text] [Related]
36. An inverse docking approach for identifying new potential anti-cancer targets. Grinter SZ; Liang Y; Huang SY; Hyder SM; Zou X J Mol Graph Model; 2011 Apr; 29(6):795-9. PubMed ID: 21315634 [TBL] [Abstract][Full Text] [Related]
37. Computational identification of a transiently open L1/S3 pocket for reactivation of mutant p53. Wassman CD; Baronio R; Demir Ö; Wallentine BD; Chen CK; Hall LV; Salehi F; Lin DW; Chung BP; Hatfield GW; Richard Chamberlin A; Luecke H; Lathrop RH; Kaiser P; Amaro RE Nat Commun; 2013; 4():1407. PubMed ID: 23360998 [TBL] [Abstract][Full Text] [Related]
38. Prima-1 and APR-246 in Cancer Therapy. Zatloukalová P; Galoczová M; Vojtěšek B Klin Onkol; 2018; 31(Suppl 2):71-76. PubMed ID: 31023027 [TBL] [Abstract][Full Text] [Related]
39. Involvement of p53 in insulin-like growth factor binding protein-3 regulation in the breast cancer cell response to DNA damage. Marzec KA; Lin MZ; Martin JL; Baxter RC Oncotarget; 2015 Sep; 6(29):26583-98. PubMed ID: 26378048 [TBL] [Abstract][Full Text] [Related]
40. Apoptosis resistance of MCF-7 breast carcinoma cells to ionizing radiation is independent of p53 and cell cycle control but caused by the lack of caspase-3 and a caffeine-inhibitable event. Essmann F; Engels IH; Totzke G; Schulze-Osthoff K; Jänicke RU Cancer Res; 2004 Oct; 64(19):7065-72. PubMed ID: 15466201 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]